(263 days)
No
The description focuses on standard post-processing techniques for calculating flow parameters from velocity-encoded MRI data, without mentioning any AI or ML algorithms.
No.
The device is a post-processing software that provides quantitative analysis and visualization of MR imaging data for diagnostic support, not therapy.
Yes
The "Intended Use / Indications for Use" section states that the parameters calculated and displayed by the software "may be useful for a trained physician in supporting the determination of a diagnosis." This explicitly indicates its role in the diagnostic process.
Yes
The device is described as "software option for use with AZE VirtualPlace workstation" and "optional post-processing software designed to be installed on and used with AZE VirtualPlace workstation". It processes existing imaging data and provides analysis, without including any hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, treatment, or prevention of disease.
- Device function: The AZE VirtualPlace - MR Flow Analysis software processes imaging data (MRI), not specimens taken from the body. It analyzes velocity-encoded MRI data to provide quantitative information about blood flow in arterial vessels and heart valves.
- Intended Use: The intended use clearly states it's for "post-processing of DICOM compliant velocity-encoded MRI imaging data for visualization and quantitative analysis." This is an imaging analysis tool, not a diagnostic test performed on a biological sample.
While the results of this software may be used by a physician to support a diagnosis, the device itself is not performing an in vitro diagnostic test. It's a medical image processing and analysis software.
N/A
Intended Use / Indications for Use
AZE VirtualPlace - MR Flow Analysis software for use with AZE VirtualPlace workstation is intended for post-processing of DICOM compliant velocity-encoded MRI imaging data for visualization and quantitative analysis of arterial vessels and heart valves. The MR Flow Analysis enables to calculate and display the parameters: mean/minimum/maximum and standard deviation of blood velocity in region of interest (ROI), velocity and volume flow as function of time, stroke volume and cardiac output, with graphs of the velocity and volume. These parameters may be useful for a trained physician in supporting the determination of a diagnosis.
Product codes
90 LLZ
Device Description
AZE VirtualPlace - MR Flow Analysis software is an optional post-processing software designed to be installed on and used with AZE VirtualPlace workstation (cleared under K060453), which accepts, transfers, displays, stores, and digitally process DICOM medical images from a variety of diagnostic imaging systems (such as CT, MRI, or from image archives) for viewing, image manipulation, communication, printing and quantification. The MR Flow Analysis retrieves velocity-encoded MRI imaging data via electric media (offline), such as CD-ROM, or digital network (online), and facilitates the visualization and quantitative analysis for arterial vessels and heart valves. The MR Flow Analysis enables to calculate blood flow velocity and flow volume in region(s) of interest (ROI[s]) from the velocity-encoded MR data, and provide quantitative and visual analysis by displaying graphical parameters such as Mean/Minimum/Maximum velocity, Standard deviation, Velocity and volume flow as function of time, Stroke volume, and Cardiac output.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
velocity-encoded MRI imaging data
Anatomical Site
arterial vessels and heart valves
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained physician
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
AZE VirtualPlace - MR Flow Analysis software is substantially equivalent to the predicate devices based on descriptive data, software features and indications for use. In addition, the AZE VirtualPlace - MR Flow Analysis software was quantitatively validated by comparing its output to that of one of the predicate devices (cmr42 Cardiac MR Software) for the same set of test images.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
AZE VirtualPlace - MR Flow Analysis software 510(k) Premarket Notification
MAY 2 4 2011
510(k) Summary
Date Prepared
May 13, 2011
Submitter
AZE, Ltd. Marunouchi Trust Tower NORTH 13F, 1-8-1 Marunouchi Chiyoda-ku, Tokyo 100-0005, Japan Phone: +81-3-3212-7721 Fax: +81-3212-7722 Contact Person: Yuki Kitajima
General Information
Proprietary Name: AZE VirtualPlace – MR Flow Analysis software Common Name: MR Flow Analysis Classification Name: System, Image Processing, Radiology CFR Reference: 21 CFR 892.2050 Class: II Product Code: 90 LLZ
Predicate Devices
MRI-FLOW analytical software package (K994282) from MEDIS medical imaging systems B.V. and cmr42 Cardiac MR Software (K082628) from Circle Cardiovascular Imaging, Inc.
Device Description
AZE VirtualPlace - MR Flow Analysis software is an optional post-processing software designed to be installed on and used with AZE VirtualPlace workstation (cleared under K060453), which accepts, transfers, displays, stores, and digitally process DICOM medical images from a variety of diagnostic imaging systems (such as CT, MRI, or from image archives) for viewing, image
1
K102534
?, 2 of 2
AZE VirtualPlace - MR Flow Analysis software 510(k) Premarket Notification
manipulation, communication, printing and quantification. The MR Flow Analysis retrieves velocity-encoded MRI imaging data via electric media (offline), such as CD-ROM, or digital network (online), and facilitates the visualization and quantitative analysis for arterial vessels and heart valves. The MR Flow Analysis enables to calculate blood flow velocity and flow volume in region(s) of interest (ROI[s]) from the velocity-encoded MR data, and provide quantitative and visual analysis by displaying graphical parameters such as Mean/Minimum/Maximum velocity, Standard deviation, Velocity and volume flow as function of time, Stroke volume, and Cardiac output.
Intended Use
AZE VirtualPlace - MR Flow Analysis software for use with AZE VirtualPlace workstation is intended for post-processing of DICOM compliant velocity-encoded MRI imaging data for visualization and quantitative analysis of arterial vessels and heart valves. The MR Flow Analysis enables to calculate and display the parameters: mean/minimum/maximum and standard deviation of blood velocity in region of interest (ROI), velocity and volume flow as function of time, stroke volume and cardiac output, with graphs of the velocity and volume. These parameters may be useful for a trained physician in supporting the determination of a diagnosis.
Technological Characteristics
AZE VirtualPlace - MR Flow Analysis software has similar technological characteristics to the currently marketed predicate devices listed above.
Performance Data (non-clinical or clinical)
AZE VirtualPlace - MR Flow Analysis software is substantially equivalent to the predicate devices based on descriptive data, software features and indications for use. In addition, the AZE VirtualPlace - MR Flow Analysis software was quantitatively validated by comparing its output to that of one of the predicate devices (cmr42 Cardiac MR Software) for the same set of test images.
Conclusions
The technological characteristics and performance data for AZE VirtualPlace - MR Flow Analysis software demonstrates it is substantially equivalent to the predicate device.
2
Image /page/2/Picture/0 description: The image shows the seal of the Department of Health & Human Services - USA. The seal features a stylized eagle or bird-like symbol with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002
- AZE: Ittd. % Mr. Mark Job Responsible Third Party Official Regulatory Technology Services, LLC 1394 25th Street NW BUFFALO MN 55313
MAY 2 4 2011
Re: K102534
Trade/Device Name: AZE VitualPlace™ – MR Flow Analysis software Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: May 17, 2011 Received: May 18, 2011
Dear Mr. Job:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
3
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours.
Mary S Patel
Mary S. Pastel, Sc.D. Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
4.0 Indication for Use statement
| 510(k) Number (if known): | Not assigned |
|---|---|
| Device-Name: | AZE VirtualPlace™ - MR Flow Analysis software |
| Indications For Use: | AZE VirtualPlace - MR Flow Analysis software option for use with AZE VirtualPlace workstation is intended for post-processing of DICOM compliant velocity-encoded MRI imaging data for visualization and quantitative analysis of arterial vessels and heart valves. The MR Flow Analysis software calculates and displays the following parameters: mean/minimum/maximum and standard deviation of blood velocity in the selected region of interest (ROI); velocity and volume flow as function of time; stroke volume and cardiac output, and provides graphs of the velocity and volume. These parameters may be useful for a trained physician in supporting the determination of a diagnosis. |
Prescription Use _____________________________________________________________________________________________________________________________________________________________ Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Mausfostel
(Division Sign-Off)
Division of Radiologic Office of In Vitro Diagnostic Devices
Office of In Vitro Diagnostic Device Evaluation and Sefety
510K K102534
Page 4-1 of 1
AZE, Ltd.